Multiple motor regions of the brain are underactive during lower limb movements in Parkinson's patients, according to a study.

Published Date: 26 Apr 2023

Parkinson's disease is a prevalent neurodegenerative condition that impairs movement. A person's gait and balance are eventually affected by the disease, which frequently starts with minor hand tremors.

Read Full News

Latest News

Cladribine Maintains Efficacy, Safety Profile in Older Patients With Multiple Sclerosis Marco Meglio

Real-world phase 4 data show cladribine keeps relapse rates low and safety steady in relapsing MS patients, including those 65+.

Subgroup Signals Emerge for rFVIIa in Acute Intracerebral Hemorrhage in Phase 3 FASTEST Trial Marco Meglio

FASTEST finds rFVIIa curbs ICH bleeding fast but adds clot risk; ultra-early and spot-sign patients show promise as Part 2 continues.

Late-Breaking CHOICE 2 Data Indicate Alteplase Displayed Improved Stroke Recovery Louie Pasculli

Adding intra-arterial alteplase after successful endovascular thrombectomy significantly improved 90-day functional outcomes in patients with large-vessel acute ischemic stroke, according to late-breaking data from the phase 3 CHOICE2 trial.

Cladribine Tablets Show Ability to Improve or Stabilize Cognitive Function in Patients With Relapsing Multiple Sclerosis Noah Stansfield

The analysis included 280 patients from CLARIFY-MS extension and 219 patients from MAGNIFY-MS extension, a total of 499 patients with at least 4 years of follow-up.

Real-World Data Analysis Highlight Clinical Profiles and Inebilizumab Use Patterns in NMOSD Isabella Ciccone, MPH

A cohort analysis, presented at ACTRIMS 2026, provided insight into the clinical characteristics, disease burden, and treatment sequencing of patients with neuromyelitis optica spectrum disorder treated with inebilizumab.

CREST-2 Substudy Shows No Cognitive Benefit of Carotid Revascularization in Asymptomatic Carotid Stenosis Isabella Ciccone, MPH

Late-breaking data from a substudy of the CREST-2 trial revealed that carotid revascularization did not show greater improvements in cognitive function compared with intensive medical management.

Todays Updates

CD40L Inhibitor Frexalimab Enters Phase 3 FREXITE Trial of Non-Relapsing Secondary Progressive Multiple Sclerosis Marco Meglio

New phase 3 FREXCITE trial tests frexalimab CD40L inhibitor in nrSPMS, comparing on-body subcutaneous vs IV dosing

Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers Marco Meglio

Findings from a phase 1 study indicated that Lucid-21-302 was generally well tolerated and exhibited dose-proportional exposure, warranting additional study in a phase 2 trial for multiple sclerosis.

Oral Semaglutide May Reduce Heart Failure Risk in Patients With T2D

Oral Semaglutide May Reduce Heart Failure Risk in Patients With T2D

Upadacitinib Switch from Dupilumab Effective in Head and Neck Atopic Dermatitis

Upadacitinib Switch from Dupilumab Effective in Head and Neck Atopic Dermatitis

Todays Updates

CD40L Inhibitor Frexalimab Enters Phase 3 FREXITE Trial of Non-Relapsing Secondary Progressive Multiple Sclerosis Marco Meglio

New phase 3 FREXCITE trial tests frexalimab CD40L inhibitor in nrSPMS, comparing on-body subcutaneous vs IV dosing

Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers Marco Meglio

Findings from a phase 1 study indicated that Lucid-21-302 was generally well tolerated and exhibited dose-proportional exposure, warranting additional study in a phase 2 trial for multiple sclerosis.

Oral Semaglutide May Reduce Heart Failure Risk in Patients With T2D

Oral Semaglutide May Reduce Heart Failure Risk in Patients With T2D

Upadacitinib Switch from Dupilumab Effective in Head and Neck Atopic Dermatitis

Upadacitinib Switch from Dupilumab Effective in Head and Neck Atopic Dermatitis

Latest News

Real-world phase 4 data show cladribine keeps relapse rates low and safety steady in relapsing MS patients, including those 65+.

FASTEST finds rFVIIa curbs ICH bleeding fast but adds clot risk; ultra-early and spot-sign patients show promise as Part 2 continues.

Adding intra-arterial alteplase after successful endovascular thrombectomy significantly improved 90-day functional outcomes in patients with large-vessel acute ischemic stroke, according to late-breaking data from the phase 3 CHOICE2 trial.

The analysis included 280 patients from CLARIFY-MS extension and 219 patients from MAGNIFY-MS extension, a total of 499 patients with at least 4 years of follow-up.

A cohort analysis, presented at ACTRIMS 2026, provided insight into the clinical characteristics, disease burden, and treatment sequencing of patients with neuromyelitis optica spectrum disorder treated with inebilizumab.

Late-breaking data from a substudy of the CREST-2 trial revealed that carotid revascularization did not show greater improvements in cognitive function compared with intensive medical management.

News All Time

This Week on NeurologyLive® — February 2, 2026 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Anti-IL6R Therapy Effective in Reducing NMOSD and MOGAD Disease Activity Louie Pasculli

Anti–interleukin-6 receptor therapy may offer a new treatment option for patients with NMOSD and MOGAD who do not respond to rituximab, according to new findings.

NeurologyLive® Brain Games: February 1, 2026 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the ACTRIMS and its history!

Women Physicians Day 2026: Sex-Specific Clinical Considerations in Women With Epilepsy Isabella Ciccone, MPH, Page B. Pennell, MD, FAES, FAAN, FANA

Epilepsy titan Page B. Pennell, MD, FAES, FAAN, FANA, outlined key hormonal, reproductive, and treatment-related factors that influence epilepsy management and outcomes for women in different life stages.

National Women Physicians Day: Strengthening the Pathway for Women Physicians in Neuroscience Marco Meglio, Claire Henchcliffe, MD, DPhil

Claire Henchcliffe, MD, DPhil, an international leader in Parkinson disease research, reflects on mentorship, leadership development, and the systemic changes needed to support long-term success for women in neurology and clinical neuroscience.

Women Physicians Day 2026: Supporting Women With MS Through Reproductive and Life Stage Transitions Isabella Ciccone, MPH, Katrina Bawden, MSN, MSCN, FNP-C, Parisa Khosravi, DO, April Erwin, MD

In honor of National Women Physicians Day, held February 3, 2026, a trio of women clinicians highlighted the importance of individualized care for women living with multiple sclerosis.

NeurologyLive® Friday 5 — January 30, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 30, 2026.

AAN Publishes First-Ever Guideline for Functional Seizure Care Management Marco Meglio

The AAN's new guideline enhances diagnosis and management of functional seizures, emphasizing psychological interventions and addressing care gaps for better patient outcomes.

Taysha Doses First Patient in Pivotal Trial for Rett Syndrome Gene Therapy TSHA-102, Aligns With FDA on BLA Plans Noah Stansfield

Specifically, the alignment relates to a separate, planned clinical trial referred to as ASPIRE.

Ocugen’s Stargardt Gene Therapy OCU410ST Provides +6-Letter Gain in BCVA-Evaluable Patients in Phase 1 Trial Noah Stansfield

With regard to safety, there were no serious adverse events (AEs) or AEs of special interest deemed related to OCU410ST reported in the study.

Higher CTE Stages Linked to Increased Dementia Risk, Postmortem Analysis Shows Louie Pasculli

A study of 614 brain donors revealed that individuals with stage III or IV CTE face the greatest risk of dementia.

New 3-Year EMBARK Data Highlights Continued Therapeutic Effect of Gene Therapy Elevidys in Duchenne Marco Meglio

New findings from the EMBARK study highlight Elevidys' significant long-term benefits in slowing Duchenne muscular dystrophy progression in young patients.

Phase 2 Study of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy: The REVISE Trial Isabella Ciccone, MPH

The REVISE trial, a phase 2 study evaluating GenSight Biologics’ lenadogene nolparvovec in patients with Leber hereditary optic neuropathy, is expected to begin in January 2026.

FDA Lifts Clinical Hold on Intellia’s Trial for Gene Editing Therapy Nex-Z in ATTRv-PN, Places Holds on REGENXBIO MPS Trials Noah Stansfield

Intellia’s trial for nex-z in ATTR-CM remains under clinical hold.

NeuroVoices: Kathrin LaFaver, MD, FAAN, DipABLM, on What’s Ahead for Movement Disorder Care in 2026 Kathrin LaFaver, MD, FAAN, DipABLM, Isabella Ciccone, MPH

The neurologist in the Department of Neurology at Saratoga Hospital Medical Group shared what excites her most about the future of neurology, specifically for movement disorders, in 2026.

Real-World Study Provides Support for Lamotrigine in Treating Non-Dystrophic Myotonias Louie Pasculli

Trial data showed that treatment with lamotrigine reduced myotonia severity in adults with genetically confirmed non-dystrophic myotonias, with sustained benefit and an acceptable safety profile.

Recommended News For You

In Sickle Cell Disease, Lovo-Cel is "Life-Changing, Transformative.".

FDA Authorizes Three Different Uses for Injectable Antibiotic.

Neural networks and label-free microscopy enable accurate detection of pancreatic tumors

Remote monitoring can improve recovery from cancer surgery

Olaparib-Abiraterone in mCRPCs Selected by Biomarkers Outperforms Each Agent by Itself.

Can the way we talk about cancer change how we interact with the disease?

Browse the NBE-Released Curriculum at FNB Head and Neck Oncology.

Recommended Articles For You

Feline Anemia: Diagnosis and Treatment with Focus on Rasburicase Complications 

Lactic Acid-Linked lncRNAs in Wilms Tumor: Decoding the Tumor Microenvironment & Prognosis 

All You Need To Know About Partial Thromboplastin Time (PTT) Test 

Unlocking the Potential of Polatuzumab for Cancer Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Getting More Done With Less Blood.

2.

New imaging solution could help improve survival for patients with recurring prostate cancer

3.

A researcher has found that yoga exhibits the "most improvement" in helping long-term cancer survivors restore their brain health.

4.

Bladder cancer link to explosive ordnance exposure among Army veteran bomb disposal officers

5.

Taking Charge of Your Cancer Journey.

1.

Exploring Innovative Approaches to Esophageal Cancer Treatment

2.

Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training

3.

Hemophilia: Pathophysiology, Genetics, and Treatment Advances

4.

Toripalimab + Nab-Paclitaxel in PD-L1+ TNBC: Phase 3 TORCHLIGHT Trial Results

5.

Advancements in Survival Mechanisms and Prognostic Determinants in Acute Myeloid Leukemia

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial

2.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV

3.

Post Progression Approaches After First-line Third-Generaion ALK Inhibitors

4.

A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months

5.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot